| Ytd | -50.66% | |
| 1y | -81.51% |
| Open | 1.85 | Prev Close | 1.78 | Low | 1.75 | High | 1.90 | Mkt Cap | 7.90M |
| Vol | 48.34K | Avg Vol | 52.93K | EPS | -4.52 | P/E | N/A | Forward P/E | -0.73 |
| Beta | 2.13 | Short Ratio | 3.31 | Inst. Own | 7.03% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-18 | 50-d Avg | 2.29 | 200-d Avg | 3.46 | 1yr Est | 13.20 |
On June 29, 2026, Jeffrey Church informed Imunon, Inc. (the "Company") of his intent to ret
IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated im
Includes up-front issuance of preferred stock for $2.5 million and secured promissory notes for $7.7